First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
A phase 1/2 trial of Fulvestrant, Ribociclib, Palbociclib, Exemestane, Tamoxifen and Abemaciclib in advanced solid tumours, run by Eli Lilly and Company, now recruiting.
Overview
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05768139 by Eli Lilly and Company, with 880 participants planned, started 2023-04-17 and due to reach its primary completion in 2030-07. Interventions recorded: STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole and Anastrozole.
Similar pages
not linked directly; found by shared links- TrialCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
Shares Tamoxifen, Abemaciclib, Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
Shares Abemaciclib, Fulvestrant, Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Shares Exemestane, Tamoxifen, Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Shares Abemaciclib, Fulvestrant, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
- TrialA Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Shares Ribociclib, Abemaciclib, Palbociclib, Metastatic cancer (cancer that has spread) and the tag pipeline.